[ILUG-Social] BioStock News
delavan61 at hotmail.com
delavan61 at hotmail.com
Wed Nov 29 06:35:55 GMT 2000
Nov 17, 2000 * * * * * * * * * * * * * * Investors Spotlight
by Looknofurther * * * * * * * * * * * * Bioenvision.co.uk (BIOV.OB)
LEAD PRODUCT LAUNCH
Reports Substantive Progress On Four Platform Technologies
BIOENVISION INC. - OTCBB Symbol: BIOV.OB
In a recent press release President & CEO Chris Wood
commented, "The global anti-cancer therapy market, presently
valued at approximately $16 billion, is poised for considerable
further growth. We believe this market will double in the next
4 years. This expansion will be driven by innovative new therapies
which should dramatically improve control over the disease.
During the past fiscal year, we made substantive progress
developing our four platform technologies. We intend marketing
our breast cancer drug, Modrefen, in 2001. This product will
compete in the market-place with drugs such as Genentech's
(NYSE:DNA - news) Herceptin but it's novel mode of action puts
it in a specific therapeutic niche. Extensive clinical trials
showed that Modrefen is effective in up to 55% of patients with
breast cancer who relapse after hormone therapy with drugs such
as Astra Zeneca's (NYSE:AZN - news) Tamoxifen."
Dr. Wood continued, "During the next 12 months we intend to
find a co-development partner for our anti-leukemia agent,
Clofarabine. This drug is in Phase II clinical trials and
early results are encouraging. This product will compete with
Fludarabine, which is marketed in the USA by Berlex, a subsidiary
of Schering AG (717200D) and Pentotatin which is marketed by
Supergen (NASDAQ:SUPG - news). We continue to make substantive
progress on our Gene Therapy platform. In the past year the
team added a second gene to the vector and conducted successful
pre-clinical trials. The results have confirmed the ability of
the vector to transfer DNA to skeletal muscle and for release of
gene product into the blood stream. In an earlier clinical trial,
with the albumin gene attached to the vector, patients with low
serum albumin levels due to end-stage liver disease, had serum
levels returned to the normal range after treatment. We believe
that these agents have considerable commercial possibilities."
Bioenvision is a development-stage, biopharmaceutical
company primarily engaged in the development of products
and technologies for the treatment of cancer. Bioenvision has
acquired development, manufacturing and marketing rights to
four technologies from which a range of products have been
derived and from which additional products may be developed
in the future. Bioenvision aims to continue developing its
existing platform technologies, acquire additional technologies
and products with multiple uses, and commercialize products
for the multi-billion dollar cancer treatment market.
Bioenvision expects to begin marketing Trilostane for the
treatment of post-menopausal breast cancer on a commercial
scale in the United States and Europe in the second quarter
of 2001. The product is already FDA-approved in the United States
for another use. Bioenvision plans to apply to use the drug in
the United States for treatment of hormone sensitive cancers,
such as breast cancer and advanced prostrate cancer. In addition,
three of the other products and technologies to which Bioenvision
has acquired rights are presently being tested in clinical trials,
and an additional eight are in the pre-clinical stage of development.
Assuming the successful completion of clinical trials, Bioenvision
anticipates that by the end of 2002, five of Bioenvision's products
and technologies will have received regulatory approval for
specific disease (primarily cancer) treatment indications in the
United States or Europe and seven will be in the final stages of
the clinical trial process.
Bioenvision has had discussions with potential development
partners over the past year and plan to continue to explore the
possibilities for co-development and sub-licensing. Bioenvision
expects to enter into a co-development agreement for at least
one of our products within the next few months although there
can be no assurances that any such agreement will be reached.
Bioenvision is also working on a fourth group of compounds that
act as cytostatic agents by stopping the growth of cancer cells.
There are at least three potential products in this category,
one of which is set for a Phase I clinical trial in the coming
year. These compounds are at an early stage of development but
the Company expects these agents to fill the product pipeline
for the future.
In March 2000, Bioenvision recieved an equity investment of
$2 million from Bioaccelerate BVI, a Swiss-based investment
company which enabled the Company to move ahead in its business
plan during 2000. Bioaccelerate has an option to invest an
additional $4 million in the Company and that investment relates
to certain milestones in the coming 12 months.
The following is a description of Bioenvision's current portfolio
of technologies, products and products in development.
Product / Disease intended / Current stage /Anticipated Time
to be treated of Development Until Marketed
Modrefen / Breast cancer / At market / - - -
Abetafen / Prostate cancer / Phase II trials / 2 years
Clofarabine / Leukemia, Lymphoma / Phase II trials / 18 months
Clofarabine / Solid tumors / Phase I trials / 2 years
Cytostatics / Bladder cancer / Phase I trials / 3 years
RA inhibitor / Leukemia / Pre-clinical / 4 years
Hormone blocker / Prostate cancer / Pre-clinical / 4 years
Product 1 / Leukemia / Phase I, II / 3 years
Product 2 / Cancer support / Phase I, II / 3 years
Trilostane / Cushing's disease / At market / - - -
Trilostane / Alzheimer's disease / Pre-clinical / 2 years
Clofarabine / Transplantation / Phase I trials / 3 years
Gene Therapy / Vaccines, Cirrhosis,
Diabetes, MS / R & D / 5 years
The Company was founded by Chris Wood and financed by
Kevin Leech, who were responsible for the first two public
biotech companies in Europe in 1987, being Medeva plc
and ML Laboratories plc respectively.
London School of Pharmacy
University of Cardiff
National Institute of Cancer, Bari, Italy
University College, London
MD Anderson Cancer Center, Houston, Texas
Southern Research Institute, Alabama
Memorial Sloan Kettering Cancer Institute, New York
Imperial College, London
Bioenvision's strategy is to license and acquire products ready
for clinical trials or at a late stage of development, and to use
the expertise of Bioenvision's management to take the products
through clinical trials and to commercially position the products
for today's marketplace.
Bioenvision will establish an oncology sales force for the
North American market while establishing a joint venture
sales force in Europe.
This will give Bioenvision the ability to distribute products from
Bioenvision's own pipeline as well as products from other biotech
companies looking for a dedicated oncology distribution chain.
Looknofurther is an independent electronic publication providing information on selected public companies.
Any company profiled by Looknofurther pays cash or stock consideration for the electronic dissemination of the company's information for a specified time period and/or our comments about the company and/or our development of the company's website. Section 17 (b) of the Securities Act of 1933 requires that Looknofurther fully disclose the type consideration (i.e. cash, free trading stock, restricted stock, resrticted stock with regisrtation rights, stock options, stock warrants, or other type consideration) and the specific amount of the consideration our company receives or will receive, directly or indirectly, from an issuer, underwriter or dealer.
No information contained in this publication should be considered as a solicitation to purchase or sell the securities of the profiled companies.
Looknofurther is not a registered investment advisor or a registered securities broker dealer. We do not undertake or represent to make investment reccomendations or advise pertaining to the purchase or sale of the securities mentioned in our publications. The information contained within our publications are carefully compiled by Looknofurther based on our sources that we believe to be reliable. Looknofurther, however, does not quarantee the accuracy of any information contained in our publications. Looknofurther, moreover, does not endorse independently verify, or assert the truthfullness or reliablility of any statements or data made by us or the profiled companies in our publications. Investors should not rely solely on the information contained in our publications. Instead, investors should use the information provided on the profiled companies only as a starting point for conducting additional research that will permit them to form their own opinions regarding an investment in the profiled company's securities. The receipt of the information contained in our publications shall not create, under any circumstance, any implication that there has been no change in the affairs of the profiled company since the date of the profiled company press releases or other information disseminated via our publications.
The information contained in our publications may pertain to small cap and/or thinly traded securities which by there very nature involve an extremely high degree of risk. An investment in these type of securities could result in the loss of some or all an investment in the company. In addition, due to the illiquid nature of some of these securities, an investor may find or encounter difficulties liquidating the securities.
Looknofurther may liquidate the stock consideration it receives at any time it deems it appropriate to do so. The liquidation of our stock may have a negative impact on the securities of the company liquidated, including decreased market value and/or dilution of the company's securities.
The following company has agreed to pay Looknofurther to: distribute the company's information and reports in an email newsletter. Looknofurther has agreed to electronically disseminate this publication for $2000.
You are currently subscribed to Looknofurther, to unsubscribe send a blank email to: cassie380 at excite.com
More information about the Social